Financial outlook for 2024 2024 is a pivotal year from a commercial perspective. In addition to the launch of EBGLYSS® in various European territories (led by Germany, where it was launched in December 2023 and is expected to be the primary market for the product in 2024), we expect significant growth of the rest of the dermatology portfolio across Europe (primarily Ilumetri®, Wynzora®, and Klisyri®), along with recent acquisitions in Spain (Prometax® and the Physiorelax® portfolio). In addition to maximizing our growth drivers, we will also remain focused on unlocking the potential of our late-stage pipeline, while strengthening the early-stage pipeline with exciting new assets. FDA submission for the Klisyri® large field label extension in the United States has been completed, with an approval anticipated by mid-2024. Additionally, we are expecting progress in various projects that we have in early development stages (linked to agreements with Ichnos Sciences, Simcere, etherna, and Evotec, among others). We will continue to focus on other M&A operations that align with the commercial strategy, while maintaining a prudent financial approach. 2024 guidance: We expect Net Sales to grow by high-single digit compared to 2023 Net Sales of €894.5 MM, and Total EBITDA to reach between €175 MM and €190 MM. For the full financial statements, please visit: www.almirall.com/investors Stock performance and shareholders Almirall's share price on 31st December, 2023 was at €8.43 and the total market capitalization landed at €1,764 MM by year-end. Highest intraday level (€) Lowest intraday level (€) Actual annual volume (€) Daily average volume (€) Trading days Number of shares Free Float Market Capitalization (€ 31st December, 2023) Annual volume (number of shares) Average daily volume (number of shares) Year closing (€) 8.43 12.97 7.16 667,550,368 255 2,617,845 209,393,724 40% 1,764,142,124 76,306,604 299,242 Almirall share price in 2023. Main indicators Source: Bloomberg & BME Exchange